Literature DB >> 11120695

Plasma cytokine parameters and mortality in patients with chronic heart failure.

M Rauchhaus1, W Doehner, D P Francis, C Davos, M Kemp, C Liebenthal, J Niebauer, J Hooper, H D Volk, A J Coats, S D Anker.   

Abstract

BACKGROUND: Inflammatory immune activation is an important feature in chronic heart failure (CHF). Little is known about the prognostic importance of tumor necrosis factor-alpha (TNF-alpha), soluble TNF-receptor 1 and 2 (sTNF-R1/sTNF-R2), interleukin-6 (IL-6), and soluble CD14 receptors (sCD14) in CHF patients. METHODS AND
RESULTS: In 152 CHF patients (age 61+/-1 years, New York Heart Association [NYHA] class 2.6+/-0.1, peak VO(2) 17.3+/-0.6 mL. kg(-1). min(-1), mean+/-SEM) plasma concentrations of immune variables were prospectively assessed. During a mean follow-up of 34 months (>12 months in all patients), 62 patients (41%) died. Cumulative mortality was 28% at 24 months. In univariate analyses, increased total and trimeric TNF-alpha, sTNF-R1, and sTNF-R2 (all P</=0.0001), sCD14 (P=0.0007), and IL-6 (P=0.005) predicted 24-month mortality. With multivariate analysis and receiver operating characteristics, sTNF-R1 emerged among all cytokine parameters as the strongest and most accurate prognosticator in this CHF population, regardless of follow-up duration and independently of NYHA class, peak VO(2), VE/VCO(2) slope, left ventricular ejection fraction, and wasting (P<0.001). The receiver operating characteristic area under the curve for sTNF-R1 was greater than for sTNF-R2 at 6, 12, and 18 months (all P<0.05).
CONCLUSIONS: sTNF-R1 was the strongest and most accurate prognosticator, independent of established markers of CHF severity. Assessment of sTNF-R1 may be useful in identifying patients who are at high risk of death and in monitoring patients undergoing anti-TNF-alpha treatment.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11120695     DOI: 10.1161/01.cir.102.25.3060

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  181 in total

1.  Are cardiovascular diseases a subspeciality of clinical immunology?

Authors:  Pier Luigi Meroni; Piersandro Riboldi
Journal:  Clin Rev Allergy Immunol       Date:  2002-12       Impact factor: 8.667

Review 2.  Statins and the role of nitric oxide in chronic heart failure.

Authors:  Stephan von Haehling; Stefan D Anker; Eberhard Bassenge
Journal:  Heart Fail Rev       Date:  2003-01       Impact factor: 4.214

3.  Inflammatory mediators in chronic heart failure: an overview.

Authors:  Stefan D Anker; Stephan von Haehling
Journal:  Heart       Date:  2004-04       Impact factor: 5.994

4.  Pediatric and adult dilated cardiomyopathy represent distinct pathological entities.

Authors:  Meghna D Patel; Jayaram Mohan; Caralin Schneider; Geetika Bajpai; Enkhsaikhan Purevjav; Charles E Canter; Jeffrey Towbin; Andrea Bredemeyer; Kory J Lavine
Journal:  JCI Insight       Date:  2017-07-20

5.  Soluble tumor necrosis factor receptors and heart failure risk in older adults: Health, Aging, and Body Composition (Health ABC) Study.

Authors:  Catherine N Marti; Hassan Khan; Douglas L Mann; Vasiliki V Georgiopoulou; Kirsten Bibbins-Domingo; Tamara Harris; Annemarie Koster; Anne Newman; Stephen B Kritchevsky; Andreas P Kalogeropoulos; Javed Butler
Journal:  Circ Heart Fail       Date:  2013-12-09       Impact factor: 8.790

6.  Paradox of circulating advanced glycation end product concentrations in patients with congestive heart failure and after heart transplantation.

Authors:  A Heidland; K Sebeková; A Frangiosa; L S De Santo; M Cirillo; F Rossi; M Cotrufo; A Perna; A Klassen; R Schinzel; N G De Santo
Journal:  Heart       Date:  2004-11       Impact factor: 5.994

Review 7.  Muscle wasting and cachexia in heart failure: mechanisms and therapies.

Authors:  Stephan von Haehling; Nicole Ebner; Marcelo R Dos Santos; Jochen Springer; Stefan D Anker
Journal:  Nat Rev Cardiol       Date:  2017-04-24       Impact factor: 32.419

8.  Prognostic significance of biomarkers in predicting outcome in patients with coronary artery disease and left ventricular dysfunction: results of the biomarker substudy of the Surgical Treatment for Ischemic Heart Failure trials.

Authors:  Arthur M Feldman; Douglas L Mann; Lilin She; Michael R Bristow; Alan S Maisel; Dennis M McNamara; Ryan Walsh; Dorellyn L Lee; Stanislaw Wos; Irene Lang; Gretchen Wells; Mark H Drazner; John F Schmedtje; Daniel F Pauly; Carla A Sueta; Michael Di Maio; Irving L Kron; Eric J Velazquez; Kerry L Lee
Journal:  Circ Heart Fail       Date:  2013-04-12       Impact factor: 8.790

Review 9.  Biologics and heart failure in rheumatoid arthritis: are we any wiser?

Authors:  Maria I Danila; Nivedita M Patkar; Jeffrey R Curtis; Kenneth G Saag; Gim Gee Teng
Journal:  Curr Opin Rheumatol       Date:  2008-05       Impact factor: 5.006

10.  Relation of baseline plasma phospholipid transfer protein (PLTP) activity to left ventricular systolic dysfunction in patients referred for coronary angiography.

Authors:  Erdal Cavusoglu; Jonathan D Marmur; Sandeep Chhabra; Vineet Chopra; Calvin Eng; Xian-Cheng Jiang
Journal:  Atherosclerosis       Date:  2009-04-17       Impact factor: 5.162

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.